EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Atopic dermatitis in clinical practice: Symptom control, flare prevention, and impact on quality of life

Isabelle Pacheco Silveira, Flávio Rui Bezerra de Souza Júnior, Antônio Fachini Sanches Fernandes, Vinícius Cerri Bertoletti, Miguel Faustino Rickheim

International Health Sciences Review · 13.08.2026 · 2 (4)

DOI: 10.70164/ihsr.v2i4.210 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Health Sciences Review, online erschienen am 13.08.2026. Verfasst von Isabelle Pacheco Silveira und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atopic dermatitis is a chronic, relapsing inflammatory skin disease in which visible lesions represent only part of the burden. Persistent itch, sleep loss, recurrent infection, treatment workload, and psychosocial impairment may remain clinically important even when objective signs appear limited. This structured narrative review critically examined multidimensional assessment, barrier-directed care, topical anti-inflammatory treatment, proactive flare prevention, systemic escalation, and quality-of-life outcomes. PubMed/MEDLINE, the Cochrane Library, SciELO, LILACS, and current guide line repositories were searched in August 2026, prioritizing publications from 2011 onward while retaining earlier landmark evidence. Effective management depends on matching treatment intensity to both inflammatory activity and patient-experienced burden. Moisturizers support barrier care but rarely replace anti-inflammatory therapy. Topical corticosteroids and calcineurin inhibitors remain central, and proactive intermittent treatment reduces relapse at recurrent sites. For moderate-to-severe disease, biologics and oral Janus kinase inhibitors provide substantial benefit, although speed, safety, monitoring, comorbidities, age, pregnancy, access, and preferences determine selection. Control should be assessed through validated measures of signs, symptoms, long-term control, and quality of life. A treat-to-target model based on shared decisions is the most coherent strategy for preventing undertreatment and reducing cumulative disease burden.

Zitieren

APA

Silveira, I. P., Júnior, F. R. B. D. S., Fernandes, A. F. S., Bertoletti, V. C., & Rickheim, M. F. (2026). Atopic dermatitis in clinical practice: Symptom control, flare prevention, and impact on quality of life. International Health Sciences Review, 2(4). https://doi.org/10.70164/ihsr.v2i4.210

Vancouver

Silveira IP, Júnior FRBDS, Fernandes AFS, Bertoletti VC, Rickheim MF. Atopic dermatitis in clinical practice: Symptom control, flare prevention, and impact on quality of life. International Health Sciences Review. 2026;2(4). doi:10.70164/ihsr.v2i4.210

BibTeX
@article{Silveira2026,
  author = {Silveira, Isabelle Pacheco and Júnior, Flávio Rui Bezerra de Souza and Fernandes, Antônio Fachini Sanches and Bertoletti, Vinícius Cerri and Rickheim, Miguel Faustino},
  title = {Atopic dermatitis in clinical practice: Symptom control, flare prevention, and impact on quality of life},
  journal = {International Health Sciences Review},
  year = {2026},
  volume = {2},
  number = {4},
  doi = {10.70164/ihsr.v2i4.210}
}
Kostenlos starten →